Cancer letters, 2015-10, Vol.367 (1), p.12-17
2015
Details
- Autor(en) / Beteiligte
- Titel
- Androgen deprivation of prostate cancer: Leading to a therapeutic dead end
- Ist Teil von
- Cancer letters, 2015-10, Vol.367 (1), p.12-17
- Ort / Verlag
- Ireland: Elsevier Ireland Ltd
- Erscheinungsjahr
- 2015
- Link zum Volltext
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Highlights • Androgen deprivation therapy (ADT) leads to numerous molecular alterations in prostate cancer. • ADT promotes more aggressive behavior and metastasis of tumor cells. • ADT ends in incurable castration resistant disease. • ADT of advanced prostate cancer leads to a reduced efficacy of anticancer agents. • Therapeutic intervention seems to be indicated before castration resistance occurs.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0304-3835eISSN: 1872-7980DOI: 10.1016/j.canlet.2015.06.021Titel-ID: cdi_proquest_miscellaneous_1701893324
- Format
- –
- Schlagworte
- Androgen Antagonists - adverse effects, Androgen Antagonists - therapeutic use, Androgen deprivation therapy, Androgens, Animals, Antineoplastic Agents, Hormonal - adverse effects, Antineoplastic Agents, Hormonal - therapeutic use, Cancer therapies, Castration resistance, Chemotherapy, Diabetes, Disease Progression, Drug Design, Drug Resistance, Neoplasm, Drugs, Gene expression, Hematology, Oncology and Palliative Medicine, Humans, Ligands, Male, Metastasis, Molecular alterations, Molecular Targeted Therapy, Mortality, Neoplasm Recurrence, Local, Patients, Prostate cancer, Prostatic Neoplasms, Castration-Resistant - drug therapy, Prostatic Neoplasms, Castration-Resistant - metabolism, Prostatic Neoplasms, Castration-Resistant - mortality, Prostatic Neoplasms, Castration-Resistant - pathology, Proteins, Regulatory approval, Signal Transduction - drug effects, Studies, Testosterone, Treatment Outcome, Tumors